# US 2020/0003780 A1 · Methods of prognosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0003780 A1
- Document ID: US20200003780A1
- Status: Published application
- Kind: A1
- Application number: 16/565,542
- Filed: 2019-09-10
- Published: 2020-01-02
- Earliest claimed: 2007-10-22
- Assignees: St. Vincent's Hospital Sydney Limited
- Applicants: St Vincent's Hospital Sydney Limited
- Inventors: Samuel Norbert BREIT; David Alexander BROWN; Henrik GRONBERG
- Web page: https://patentgrep.com/patent/US20200003780A1

## CPC

- G01N 33/57555: of the prostate
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 2333/495: Transforming growth factor [TGF]
- G01N 2333/52: Assays involving cytokines
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to the field of medical prognostics. In particular, the invention relates to methods for predicting prostate cancer progression and overall survival prognosis in a subject involving the detection of elevated amounts of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample such as serum.

## Claims

### Claim 1

A method of prognosis of overall survival of an apparently healthy subject, the method comprising detecting an elevated amount of MIC-1 in a test body sample from said subject, wherein the elevated amount of MIC-1 is associated with an increased likelihood of death of the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the elevated amount of MIC-1 in a test body sample predicts an increased likelihood of death from any cause other than accident or misadventure.

### Claim 3 (depends on 1)

The method of claim 1, wherein the elevated amount of MIC-1 predicts an increased likelihood of death of the subject within a period of 10 years of taking the test body sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein the elevated amount of MIC-1 predicts an increased likelihood of death of the subject within a period of 5 years of taking the test body sample.

### Claim 5

A method of prognosis of prostate cancer in a male subject, the method comprising detecting an elevated amount of MIC-1 in a test body sample from the subject, wherein the elevated amount of MIC-1 is associated with an increased likelihood of prostate cancer progression.

### Claim 6 (depends on 5)

The method of claim 5, wherein the elevated amount of MIC-1 is associated with an increased likelihood of progression to aggressive prostate cancer.

### Claim 7 (depends on 5)

The method of claim 5, wherein the elevated amount of MIC-1 is associated with an increased likelihood of prostate cancer progression and an increased likelihood of death of the subject due to prostate cancer.

### Claim 8 (depends on 5)

The method of claim 5, wherein the elevated amount of MIC-1 predicts a likelihood of death of the subject from the prostate cancer within a period of 10 years of taking the sample.

### Claim 9

A method of selecting subjects, who have been diagnosed with prostate cancer, who would benefit from active treatment for prostate cancer, the method comprising detecting an elevated amount of MIC-1 in a test body sample from the subject, wherein the elevated amount of MIC-1 indicates that the subject would benefit from active treatment for prostate cancer.

### Claim 10

A method of selecting subjects for post-prostate cancer treatment adjuvant therapy, the method comprising detecting an elevated amount of MIC-1 in a test body sample from the subject, wherein the elevated amount of MIC-1 indicates that the subject would benefit from adjuvant therapy.

### Claim 11 (depends on 5)

The method of claim 5, wherein the method further comprises detecting one or more prognostic prostate cancer factors selected from the group consisting of Gleason sum, prostate specific antigen (PSA) amount, MIC-1 stromal staining and tumour-node-metastasis (TNM) stage.

### Claim 12 (depends on 1)

The method of claim 1, wherein the test body sample is a serum sample.

### Claim 13 (depends on 1)

The method of claim 1, wherein the method comprises detecting an elevated amount of MIC-1 that is >1 ng/mL.

### Claim 14 (depends on 1)

The method of claim 1, wherein the method comprises detecting an elevated amount of MIC-1 that is >1.3 ng/mL.

### Claim 15 (depends on 1)

The method of claim 1, wherein the elevated amount of MIC-1 in the test body sample is detected by:
determining the amount of MIC-1 present in the said test body sample; and
(ii) comparing said amount of MIC-1 against an amount or a range of amounts of MIC-1 present in comparative body sample(s) taken from normal subject(s).

### Claim 16 (depends on 15)

The method of claim 15, wherein the normal subject(s) are age-matched within 10 years of the age of the subject from which the relevant test body sample has been taken.

### Claim 17 (depends on 15)

The method of claim 15, wherein the normal subject(s) are age-matched within 5 years of the age of the subject from which the relevant test body sample has been taken.

### Claim 18 (depends on 1)

The method of claim 1, wherein the elevated amount of MIC-1 in a test body sample is an increase in the amount of MIC-1 within a subject detected using serial measurement by:
(i) determining the amount of MIC-1 present in the said test body sample; and
(ii) comparing said amount of MIC-1 against an amount or a range of amounts of MIC-1 present in comparative body sample(s) taken from the same subject at an earlier time point.

### Claim 19 (depends on 15)

The method of claim 15, wherein the method comprises detecting an increase in the amount of MIC-1 of >0.3 ng/ml.

### Claim 20 (depends on 15)

The method of claim 15, wherein the method comprises detecting an increase in the amount of MIC-1 of >0.6 ng/ml.

### Claim 21 (depends on 1)

The method of claim 1, wherein the subject is more than 35 years of age.
